^
    Back
    Association details:
    Biomarker:RAS wild-type
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    AiRuiKa (camrelizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Clinical Trial of Camrelizumab Combined with Cetuximab and Chemotherapy Drugs to treat Ras Wild Colorectal Cancer

    Excerpt:
    ...Histologically confirmed kras wildtype; 5. ...
    Trial ID:
    ChiCTR1900027573
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Int J Cancer
    Title:

    Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study

    Published date:
    05/10/2023
    Excerpt:
    The ORR was 25% (95% confidence interval [CI]: 10.2%-49.5%), and DCR was 75% (95% CI: 50.5%-89.8%). The median PFS and OS were 6.9 (95% CI: 2.6-11.2) and 15.1 (95% CI: 6.1-24.0) months, respectively….Our study suggests that anti-EGFR retreatment therapy with cetuximab plus camrelizumab and liposomal irinotecan (HR070803) is a promising late-line treatment option with good antitumor activity and well-tolerated toxicity in RASwt mCRC patients.
    Secondary therapy:
    nanoliposomal irinotecan
    DOI:
    10.1002/ijc.34531